Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers
NCT ID: NCT00607347
Last Updated: 2011-09-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2008-02-29
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes
NCT00925119
Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure
NCT00669279
Open-Labeled PK-PD Studies of Metoprolol ER
NCT02417246
Perioperative Effect of Atenolol on Cytokine Profiles
NCT00202358
The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment
NCT00585091
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will undergo the PK study when they have been on atenolol 100 mg once daily for at least 4 weeks and on atenolol therapy (50 mg or 100 mg) for ≥ 7 weeks. They will undergo a two hour Oral Glucose Tolerance Test (OGTT), 1 hour after atenolol dosing. Blood will be drawn at 12 time points for 24 hours. Atenolol Cp will be measured in all 12 blood samples and will be correlated with the glucose/insulin measured during the OGTT.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
The subjects will be undergoing a oral glucose tolerance test.
Glucose
Oral Glucose Tolerance Test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glucose
Oral Glucose Tolerance Test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julie A. Johnson, PharmD
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida
Gainesville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GCRC grant RR00082
Identifier Type: -
Identifier Source: secondary_id
UF IRB 591-2007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.